Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Evogene Ltd. is a biotechnology company focused on developing products for the agricultural and pharmaceutical industries through its proprietary computational biology platform. The company operates primarily in Israel and leverages its unique gene discovery capabilities to enhance crop productivity and develop novel therapeutics.
Evogene generates revenue by licensing its technology and products to agricultural and pharmaceutical companies. Its competitive advantage lies in its proprietary computational biology platform, which allows for rapid identification of gene functions and potential applications, thereby reducing time-to-market for new products.
Advancements in gene discovery technology
Partnership announcements with major agricultural or pharmaceutical firms
Regulatory approvals for new products
Market adoption rates of its developed products
Regulatory changes affecting biotechnology approvals
Technological disruption from competitors with advanced gene editing tools
Emergence of new competitors in the agricultural biotech space
Potential for larger firms to acquire smaller competitors, increasing market consolidation
High operating losses leading to liquidity concerns
Dependence on external funding for R&D activities
moderate - the biotechnology sector can be sensitive to economic cycles, particularly in terms of funding for R&D and consumer spending on healthcare.
High interest rates could increase the cost of capital for R&D investments, impacting the company's ability to fund its projects and potentially delaying product launches.
minimal - the company has a negative debt/equity ratio, indicating it is not reliant on debt financing.
growth - investors looking for high-risk, high-reward opportunities in the biotech space.
high - the stock has shown significant volatility, with a 1-year return of -70.6%.
